Erratum: The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome (Journal of Addiction Medicine (2011) 5 (293-299) DOI: 10.1097/ADM.0b013e3182266a3a);The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome

Journal of Addiction Medicine

Volumn 5, Issue 4, 2011, Pages 293-299

  Wachman, Elisha M ^a,b   Newby, P K ^c,d   Vreeland, Joy ^e   Byun, John ^a,e   Bonganzi, Anthony ^c   Bauchner, Howard ^c,f   Philipp, Barbara L ^c,f  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e Department of Pharmacy ^*  (United States)

^f BOSTON MEDICAL CENTER   (United States)

Author keywords

Benzodiazepines; Buprenorphine; Methadone; Neonatal abstinence syndrome; Psychiatric medications

Indexed keywords

BUPRENORPHINE; METHADONE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; UNITED STATES; WITHDRAWAL SYNDROME;

EID: 84856868752     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000349     Document Type: Erratum

References (44)

1. Berghella V, Lim PJ, Hill MK, Cherpes J, Chennat J, Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003;189(2):312-317.
2. Binder T, Vavrinkova B. Prospective randomized comparative study of the effect of buprenorphine, methadone, and heroin on the course of pregnancy, birth weight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett 2008;29(1):80-86.
3. Briggs G, Freeman RK, Yafee SJ, eds. Drugs in Pregnancy and Lactation, 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2008.
4. Choo RE,Huestis MA, Schroeder JR, Shin AS, JonesHE. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004;75(3):253-260. (Pubitemid 38993295)
5. Colombini N, Elias R, Busuttil M, Dubuc M, Einaudi MA, Bues-Charbit M. Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone. Pharm World Sci 2008;30(3): 227-234.
6. Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG 2009;116(5): 665-671.
7. Dysart K, Hsieh HC, Kaltenbach K, Greenspan JS. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med 2007;35(4):344-346. (Pubitemid 47036964)
8. Ebner N, Rohrmeister K, Winklbaur B, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007;87(2-3):131-138. (Pubitemid 46215932)
9. Einarson A, Bonari L, Voyer-Lavigne S, et al. A multicentre prospective controlled study to determine the safety of trazadone and nefazodone use during pregnancy. Can J Psychiatry 2003;48:106.
10. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14(12):823-827. (Pubitemid 43056107)
11. Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman RA, Adam HM, Nelson NM, Weitzman ML, Wilson MH, eds. Primary Pediatric Care. St. Louis: Mosby Yearbook Inc, 1992.
12. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006;101:275-281. (Pubitemid 43351601)
13. Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat 2007;32(1):19-25. (Pubitemid 44908840)
14. Friedman J, Polifka JE, eds. Teratogenic Effects of Drugs: A Resource for Clinicians (TERIS), 2nd ed. Baltimore: The Johns Hopkins University Press, 2000.
15. Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother 2004;38(7-8):1265-1271. (Pubitemid 38802173)
16. Hendrick V, Altshuler L. Management of major depression during pregnancy. Am J Psychiatry 2002;159(10):1667-1673.
17. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002;53(1):39-49. (Pubitemid 34038614)
18. Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009;5(1):47-55.
19. Johnson RE, Jones HE, Jasinski DR, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001;63(1):97-103. (Pubitemid 32293533)
20. Jones HE, Johnson RE, JasinskiDR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005;79(1):1-10. (Pubitemid 41557119)
21. Kacinko SL, Jones HE, Johnson RE, Choo RE, Huestis MA. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther 2008;84(5):604-612.
22. Kakko J, Heilig M, Sarman I. Buprenorphine andmethadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008;96(1-2):69-78.
23. Klinger G, Merlob P. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Isr J Psychiatry Relat Sci 2008;45(2):107-113.
24. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003;348:1786-1795. (Pubitemid 36514710)
25. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006;82(3):250-257.
26. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160(2): 173-176. (Pubitemid 43213863)
27. Lim S, PrasadMR, Samuels P, Gardner DK, Cordero L.High-dosemethadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol 2009;200(1):70.e1-70.e5.
28. Martin PR, Arria AM, Fischer G, et al. Psychopharmacologic management of opioid-dependent women during pregnancy. Am J Addict 2009;18(2): 148-156.
29. Reynolds J, Parsons AV, Sweetman SC, eds. Martindale: The Extra Pharmacopoeia, 31st ed. London: Royal Pharmaceutical Society, 1996.
30. McCarthy JJ, Leamon MH, ParrMS, Anania B. High-dosemethadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol 2005;193(3 Pt 1):606-610. (Pubitemid 41261451)
31. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991;21(2):157-171.
32. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293(19):2372-2383. (Pubitemid 40676760)
33. Nanovskaya TN,Deshmukh S, Brooks M, Ahmed MS. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther 2002;300(1): 26-33. (Pubitemid 34028504)
34. Nanovskaya TN, Nekayeva IA, Hankins GD, Ahmed MS. Transfer of methadone across the dually perfused preterm human placental lobule. Am J Obstet Gynecol 2008;198(1):126.e1-126.e41.
35. Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007;164(8):1214-1220. (Pubitemid 47292410)
36. Oei J, Lui K. Management of the newborn infant affected by maternal opiates and other drugs of dependency. J Paediatr Child Health 2007;43(1-2): 9-18. (Pubitemid 44973395)
37. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365(9458):482-487. (Pubitemid 40215730)
38. Sarkar S, Donn S. Management of neonatal abstinence syndrome in the neonatal intensive care units: a national survey. J Perinatol 2006;26:15-17. (Pubitemid 43135249)
39. Schindler SD, Eder H, Ortner R, Rohrmeister K, LangerM, Fischer G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 2003;98(1):103-110. (Pubitemid 36044342)
40. Seligman NS, Salva N, Hayes EJ, Dysart KC, Pequignot EC, Baxter JK. Predicting length of treatment for neonatal abstinence syndrome inmethadoneexposed neonates. Am J Obstet Gynecol 2008;199(4):396.e1-396.e7.
41. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The NSDUH Report. Substance Use During Pregnancy: 2002 and 2003 Update. Rockville: Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2005.
42. US Department of Health and Human Services, Substance Abuse and Mental Health Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings.Washington, DC: US Department of Health and Human Services, Substance Abuse and Mental Health Administration, 2008.
43. Way CM. Safety of newer antidepressants in pregnancy. Pharmacotherapy 2007;27(4):546-552. (Pubitemid 46536236)
44. Wisner KL, Zarin DA, Holmboe ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000;157(12):1933- 1940.